Delivery Order SPE2DR25D9133-SPE2DR26FCFK2
- Not listed
- The Defense Logistics Agency has awarded a delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA 30 mg/ml syringes. DMS Pharmaceutical Group Inc. is a critical supplier within the federal pharmaceutical supply chain and has been registered in the System for Award Management since 2001. This delivery order was issued without a set-aside designation, reflecting the...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,435 to DMS Pharmaceutical Group Inc. for Fasenra 30 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 3, 2025, and represents one of numerous...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $14,661.00 to DMS Pharmaceutical Group Inc., a woman-owned small business (WOSB) pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of FASENRA 30 MG/ML SYRINGEML, a specialty pharmaceutical product, with a performance period running through September 5, 2024. This delivery order contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that...
- This firm fixed-price delivery order worth $2,443.50 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialty medication, with a completion date of September 9, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The Defense Logistics Agency awarded a $2,275.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA Pen 30 mg/ml. The delivery order, which became effective on September 5, 2025, with an ultimate completion date of September 26, 2025, will be performed in Conshohocken, Pennsylvania. This award was made without a set-aside designation, allowing the contractor to compete directly in the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $9,774.00 to DMS Pharmaceutical Group Inc. for the supply of FASENRA 30 mg/ml syringes. The contract, which carries no set-aside designation, was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform all work at its facility in Park Ridge....
- The U.S. Defense Logistics Agency (DLA) awarded a $4,887.00 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through November 8, 2024. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,330.50 firm fixed-price delivery order is for the supply of FASENRA 30 MG/ML SYRINGEML, a pharmaceutical product, with a contract completion date of June 24, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $2,443.50 on July 22, 2025, for the supply of Fasenra 30 mg/mL syringes. The contract, which has no set-aside designation, is set to be completed by July 23, 2025, and will be performed at the vendor's Park Ridge location. This delivery order is funded by the Defense Logistics Agency's Medical Supply Chain division and...
- SPE2DR25D9133Indefinite Delivery Contract
- SPE2DR25D9133-SPE2DR26FCFK2Delivery Order
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $12,468.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA 30 mg/ml syringes. The contract, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, carries no set-aside designation, indicating the awardee competed in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy designed to streamline pharmaceutical procurement for Department of Defense medical facilities worldwide. DMS Pharmaceutical Group has demonstrated substantial capability as a critical pharmaceutical supplier within the federal military medical supply chain, with its PPV-G GEN V prime contract ceiling valued at $499.9 million through December 31, 2036. The company's established performance across numerous delivery orders spanning diverse therapeutic categories—including oncology treatments, biologics, vaccines, and specialty pharmaceuticals—positions it to fulfill the specialized medical supply requirements of DoD healthcare operations globally. No subcontractor relationships are identified in the award documentation.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.5k | 11/7/25 |